Drug database vendor IMS Health has made its second acquisition in recent days, buying TTC, a data analytics and benchmarking firm.

Terms were not disclosed. TTC’s technology helps life sciences organizations plan for and negotiate the costs of clinical trials. The company serves 17 of the top 20 pharmaceutical companies and eight of the 10 largest contract research organizations, which conduct clinical trials.

IMS earlier this week further strengthened its analytics services with a buy of PharmaDeals, which has a database of business transactions, licenses, and mergers and acquisitions over 16 years. Earlier this year, IMS bought DecisionView, which sells clinical trial planning and performance software.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access